Lannett Company receives approval for doxycycline monohydrate

Journal of Drugs in Dermatology, Feb, 2006

Lannett Company, Inc., recently announced that the FDA has approved its Abbreviated New Drug Application for doxycycline monohydrate 50 mg and 100 mg tablets. This product represents a generic version of Doak Dermatologics' Adoxa tablets. This is the first generic approval of this medication used to treat acne and other bacterial infections.

Pipeline Previews is a feature that will appear in each issue. It will bring to you information on the newest drugs and medical products as they become available to the dermatological community. These features may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving FDA approval. We trust you will find this information beneficial in your practice and research.